U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 12b-25
SEC FILE NUMBER: 0-17378
CUSIP NUMBER:
NOTIFICATION OF LATE FILING
(CHECK ONE)
FORM 10-K
FORM 11-K
FORM 20-F
X FORM 10-Q
FORM N-SAR
For period Ended: April 30, 2000
Nothing in this Form Shall be construed to imply
that the Commission has verified any information
contained herein.
If the notification relates to a portion of the
filing checked above, identify the Item(s) to which
the notification relates:
_______________________________
====================================================
Part I - Registrant Information
====================================================
Vitro Diagnostics, Inc.
-----------------------
Full Name of Registrant
-------------------------
Former Name if Applicable
8100 Southpark Way, Building B-1
---------------------------------------------------------
Address of Principal Executive Office (street and number)
Littleton, CO 80120
------------------------
City, State and Zip Code
====================================================
Part II - Rules 12b-25 (b) and (c)
====================================================
If the subject report could not be filed without
unreasonable effort or expense and the registrant
seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check Box if
appropriate) X
(a) The reasons described in reasonable detail in
Part III of this form could not be eliminated
without unreasonable effort or expense;
(b) The subject annual report or semi-annual
report/portion thereof will be filed on or before
the fifteenth calendar day following the prescribed
due date; or the subject quarterly report/portion
thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c) the accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached if
applicable
====================================================
Part III - Narrative
====================================================
State below in reasonable detail the reasons why the
Form 10-K, 11-K, 20-F, 10-Q, or N-SAR or portion
thereof, could not be filed within the prescribed
time period.
The Company and its accountant need additional time
to finalize and analyse its financial statements and
prepare Management's Discussion and Analysis of
Financial Condition and Results of Operation.
====================================================
PART IV - OTHER INFORMATION
====================================================
(1) Name and telephone number of person to contact
in regard to this notification
Name: David J. Babiarz, Esq.
Area code and phone number: (303) 779-5900
(2) have all other periodic reports required under
Section 13 or 15(d) of the Securities Exchange Act
of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such
shorted period that the registrant was required to
file such reports) been filed? If the answer is no,
identify report(s).
__x__ yes
_____ no
(3) Is it anticipated that any significant change
in results of operations from the corresponding
period for the last fiscal year will be reflected by
the earnings statements to be included in the
subject report or portion thereof?
_____ yes
__x__ no
If so, attach an explanation of the anticipated
change, both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable
estimate of the results can not be made.
Vitro Diagnostics, Inc.
__________________________________________________
(NAME OF REGISTRANT AS SPECIFIED IN CHARTER)
has caused this notification to be signed on its
behalf by the undersigned thereunto duly authorized.
DATE 06/15/00
BY /s/ Roger Hurst, President
